Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: Initial experience

Annals of Nuclear Medicine

Volumn 27, Issue 1, 2013, Pages 78-83

  Nishiyama, Yuji ^a   Tateishi, Ukihide ^a   Shizukuishi, Kazuya ^a   Shishikura, Ayako ^a   Yamazaki, Etsuko ^a   Shibata, Hiroto ^a   Yoneyama, Tomohiro ^a   Ishigatsubo, Yoshiaki ^a   Inoue, Tomio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

18F fluoride; Bone imaging; Multiple myeloma; NaF; PET; PET CT

Indexed keywords

FLUORINE 18; MEDRONATE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; FLUORIDE; FLUORINE;

ADULT; ARTICLE; BONE SCINTISCANNING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; STANDARD; WHOLE BODY MRI; X RAY; MIDDLE AGED; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

FEMALE; FLUORIDES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84872685397     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0647-7     Document Type: Article

References (15)

1. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457-63.
2. Smith A, Wisloff F, Samson D, Myeloma Forum UK, Nordic Myeloma Study Group. British Committee for Standards in Haematology: guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410-51.
3. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539-43.
4. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol. 2007;137:49-63.
5. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50-5.
6. Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525-31.
7. Ludwig H, Kupman W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol. 1982;55:173-81.
8. Bataille R, Chevalier J, Rossi M, et al. Bone scintigraphy in plasma cell myeloma. A prospective study of 70 patients. Radiology. 1982;145:801-4.
9. Breyer RJ 3rd, Mulligan ME, Smith SE, et al. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol. 2006;35:632-40.
10. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989-95.
11. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
12. Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of skeletal kinetics of fluorine 18-fluoride ion and PET. J Nucl Med. 1992;33:633-42.
13. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-8.
14. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation. Hematol J. 2003;4:379-98.
15. 18F- fluoride PET/CT. J Nucl Med. 2006;47:287-97.